Mevion Medical Systems, a leading provider of compact proton therapy solutions, today announced that it has received approval from the National Medical Products Administration (NMPA) of China for its MEVION S250i Proton Therapy System. This marks the first time this advanced technology has been approved in China, making Mevion the first company to offer a compact, integrated proton solution to Chinese cancer patients.

The MEVION S250i is the first compact, integrated single-room proton therapy system that was cleared in the USA and now the first approved in China. Its innovative design combines a superconducting proton accelerator with an integrated gantry, resulting in a smaller footprint and reduced energy consumption compared to conventional proton therapy systems. The system also features HYPERSCAN pencil beam scanning technology, which allows for faster and precise tumor targeting, and Adaptive Aperture pMLC, which further minimizes damage to healthy tissue, potentially leading to fewer side effects for patients.

“We are thrilled to receive NMPA approval for the MEVION S250i,” said Dr. Tina Yu, CEO of Mevion Medical Systems. “This approval is a testament to our commitment to providing innovative and accessible cancer treatment solutions. We believe that the advancement of the MEVION S250i will make a significant contribution to the fight against cancer in China.”

The MEVION S250i offers several advantages over conventional proton therapy systems, including:

• Compact size: The system’s smaller footprint makes it easier to integrate into existing hospitals and clinics.
• Reduced cost: The MEVION S250i is more affordable than conventional proton therapy systems, making it accessible to a wider range of patients.
• Faster treatment times: The system’s HYPERSCAN technology enables faster treatment times, which can improve patient comfort and convenience.
• Enhanced precision: The Adaptive Aperture pMLC technology ensures precise dose delivery to the tumor while minimizing damage to surrounding healthy tissue.

Mevion is committed to expanding access to proton therapy in China, by providing comprehensive services to customers, such as training, education, and ongoing maintenance. This commitment builds upon Mevion's strong track record of success in the USA, where the company has established itself as the market leader in compact proton therapy. With over 50% of clinical compact centers utilizing Mevion technology, including a significant presence in NCI Comprehensive Cancer Centers, Mevion is at the forefront of clinical innovation, financial viability, and cutting-edge research in proton therapy.

About Mevion Medical Systems

Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i and MEVION S250-FIT* with HYPERSCAN pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com.

*The MEVION S250-FIT Proton Therapy System is not yet available for clinical use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241218200626/en/